Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing

Author: Vandana Singh | February 22, 2023 10:35am

  • Sorrento Therapeutics Inc (NASDAQ:SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners. 
  • The financing will provide Sorrento with immediate liquidity to continue operating its business as usual during its chapter 11 case. 
  • A hearing for final financing approval is currently set for March 29, 2023.
  • Related: Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork.
  • As of its chapter 11 filing, Sorrento had over approximately $1 billion in assets. 
  • Scilex Holding Company, majority-owned by Sorrento, is not a debtor in Sorrento's chapter 11 case. Scilex continues to operate as usual, focusing on growing revenues and offering non-opioid pain management products.
  • Latham & Watkins LLP and Jackson Walker LLP serve as legal counsel to Sorrento. M3 Partners is serving as a restructuring advisor.
  • Price Action: SRNE shares are up 10.9% at $0.44 on the last check Wednesday.

Posted In: SRNE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist